Relevant bibliographies by topics / Recurrent brief depression

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters
  4. Conference papers

Academic literature on the topic 'Recurrent brief depression'

Author: Grafiati
Published: 4 June 2021
Last updated: 11 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Recurrent brief depression.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Recurrent brief depression"

1

Kasper, Siegfried, Mara Stamenkovic, and Gabriele Fischer. "Recurrent Brief Depression." CNS Drugs 4, no. 3 (September 1995): 222–29. http://dx.doi.org/10.2165/00023210-199504030-00006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Pezawas, Lukas, Jules Angst, and Siegfried Kasper. "Recurrent brief depression revisited." International Review of Psychiatry 17, no. 1 (February 2005): 63–70. http://dx.doi.org/10.1080/00207390500064650.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Koponen, Hannu, Ulla Lepola, and Esa Leinonen. "Recurrent brief depression: A review." Nordic Journal of Psychiatry 49, no. 1 (January 1995): 39–41. http://dx.doi.org/10.3109/08039489509011882.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

ANGST, J. "COMORBIDITY OF RECURRENT BRIEF DEPRESSION." Clinical Neuropharmacology 15 (1992): 9A—10A. http://dx.doi.org/10.1097/00002826-199201001-00004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Joffe, R. T. "Tranylcypromine in recurrent brief depression." International Clinical Psychopharmacology 11, no. 4 (December 1996): 287–88. http://dx.doi.org/10.1097/00004850-199612000-00012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Stamenkovic, M., L. Pezawas, M. de Zwaan, H. N. Aschauer, and S. Kasper. "Mirtazapine in recurrent brief depression." International Clinical Psychopharmacology 13, no. 1 (January 1998): 39–40. http://dx.doi.org/10.1097/00004850-199801000-00006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Merikangas, Kathleen Ries, Werner Wicki, and Jules Angst. "Heterogeneity of Depression." British Journal of Psychiatry 164, no. 3 (March 1994): 342–48. http://dx.doi.org/10.1192/bjp.164.3.342.

Full text
Abstract:
This paper describes the application of prospective longitudinal data from an epidemiological sample of young adults to define subtypes of major depression. Depression was classified on a spectrum from subthreshold manifestation of symptoms and duration at one end, to cases with recurrent episodes of depression meeting duration criteria for major depressive episodes at the other. There was a direct relationship between the severity of depression over the longitudinal course and both duration and recurrence of depressive episodes. The subgroup of depression with recurrence of both brief and longer duration episodes could be discriminated on most of the indicators of validity including symptoms, impairment, family history, and suicide attempts. In light of the young age of this cohort, the strong history of suicide attempts and other complications of depression among the subjects with recurrent depression was striking. These findings underscore the importance of employing course as a classification criterion of depression, and the inclusion of subthreshold episodes of depression in the characterisation of course.
APA, Harvard, Vancouver, ISO, and other styles
8

Angst, J. "Recurrent Brief Depression. A New Concept of Depression." Pharmacopsychiatry 23, no. 02 (March 1990): 63–66. http://dx.doi.org/10.1055/s-2007-1014484.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Stamenkovic, M., L. Pezawas, H. N. Aschauer, M. de Zwaan, and S. Kasper. "Mirtazapine in recurrent brief depression (RBD)." Biological Psychiatry 42, no. 1 (July 1997): 242S. http://dx.doi.org/10.1016/s0006-3223(97)87906-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Carta, Mauro Giovanni, Maria Carolina Hardoy, Paolo Usai, Bernardo Carpiniello, and Jules Angst. "Recurrent brief depression in celiac disease." Journal of Psychosomatic Research 55, no. 6 (December 2003): 573–74. http://dx.doi.org/10.1016/s0022-3999(03)00547-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Recurrent brief depression"

1

Pezawas, Lukas, Hans-Ulrich Wittchen, Hildegard Pfister, Jules Angst, Roselind Lieb, and Siegfried Kasper. "Recurrent brief depressive disorder reinvestigated : a community sample of adolescents and young adults." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2013. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-103626.

Full text
Abstract:
Background: This article presents prospective lower bound estimations of findings on prevalence, incidence, clinical correlates, severity markers, co-morbidity and course stability of threshold and subthreshold recurrent brief depressive disorder (RBD) and other mood disorders in a community sample of 3021 adolescents. Method: Data were collected at baseline (age 14–17) and at two follow-up interviews within an observation period of 42 months. Diagnostic assessment was based on the Munich Composite International Diagnostic Interview (M-CIDI). Results: Our data suggest that RBD is a prevalent (2.6%) clinical condition among depressive disorders (21.3%) being at least as prevalent as dysthymia (2.3%) in young adults over lifetime. Furthermore, RBD is associated with significant clinical impairment sharing many features with major depressive disorder (MDD). Suicide attempts were reported in 7.8% of RBD patients, which was similar to MDD (11.9%). However, other features, like gender distribution or co-morbidity patterns, differ essentially from MDD. Furthermore, the lifetime co-occurrence of MDD and RBD or combined depression represents a severe psychiatric condition. Conclusions: This study provides further independent support for RBD as a clinically significant syndrome that could not be significantly explained as a prodrome or residual of major affective disorders.
APA, Harvard, Vancouver, ISO, and other styles
2

Pezawas, Lukas, Hans-Ulrich Wittchen, Hildegard Pfister, Jules Angst, Roselind Lieb, and Siegfried Kasper. "Recurrent brief depressive disorder reinvestigated : a community sample of adolescents and young adults." Cambridge University Press, 2003. https://tud.qucosa.de/id/qucosa%3A26457.

Full text
Abstract:
Background: This article presents prospective lower bound estimations of findings on prevalence, incidence, clinical correlates, severity markers, co-morbidity and course stability of threshold and subthreshold recurrent brief depressive disorder (RBD) and other mood disorders in a community sample of 3021 adolescents. Method: Data were collected at baseline (age 14–17) and at two follow-up interviews within an observation period of 42 months. Diagnostic assessment was based on the Munich Composite International Diagnostic Interview (M-CIDI). Results: Our data suggest that RBD is a prevalent (2.6%) clinical condition among depressive disorders (21.3%) being at least as prevalent as dysthymia (2.3%) in young adults over lifetime. Furthermore, RBD is associated with significant clinical impairment sharing many features with major depressive disorder (MDD). Suicide attempts were reported in 7.8% of RBD patients, which was similar to MDD (11.9%). However, other features, like gender distribution or co-morbidity patterns, differ essentially from MDD. Furthermore, the lifetime co-occurrence of MDD and RBD or combined depression represents a severe psychiatric condition. Conclusions: This study provides further independent support for RBD as a clinically significant syndrome that could not be significantly explained as a prodrome or residual of major affective disorders.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Recurrent brief depression"

1

Floresco, Stan, Robert Kessler, Ronald L. Cowan, Robert Kessler, Ronald L. Cowan, Mark Slifstein, Andrea Cipriani, et al. "Recurrent Brief Depression." In Encyclopedia of Psychopharmacology, 1142. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_3525.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Baldwin, David S., and Julia M. Sinclair. "Recurrent brief depression." In Troublesome disguises, 100–113. Chichester, UK: John Wiley & Sons, Ltd, 2014. http://dx.doi.org/10.1002/9781118799574.ch8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Angst, J. "Recurrent Brief Psychiatric Syndromes: Hypomania, Depression, Anxiety and Neurasthenia." In Basic and Clinical Science of Mental and Addictive Disorders, 33–38. Basel: KARGER, 1997. http://dx.doi.org/10.1159/000059530.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Angst, J. "Epidemiologie von „recurrent brief“ und „major depression“ — Resultate der Zürich-Studie." In Phantasie und Wirklichkeit — Fluvoxamin, 83–87. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-76935-1_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Floresco, Stan, Robert Kessler, Ronald L. Cowan, Robert Kessler, Ronald L. Cowan, Mark Slifstein, Andrea Cipriani, et al. "Recurrent Brief Depressive Disorder." In Encyclopedia of Psychopharmacology, 1142–44. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_376.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bartova, Lucie, and Lukas Pezawas. "Recurrent Brief Depressive Disorder." In Encyclopedia of Psychopharmacology, 1–4. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-27772-6_376-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Bartova, Lucie, and Lukas Pezawas. "Recurrent Brief Depressive Disorder." In Encyclopedia of Psychopharmacology, 1456–59. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-36172-2_376.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Angst, Jules, Alex Gamma, Valadeta Ajdacic, Dominique Eich, Lukas Pezawas, and Wulf Rössler. "Recurrent brief depression as an indicator of severe mood disorders." In Bipolar Disorders, 109–30. Cambridge University Press, 2005. http://dx.doi.org/10.1017/cbo9780511544019.006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lipsey, John R. "Antidepressants." In Psychiatric Aspects of Neurologic Diseases. Oxford University Press, 2008. http://dx.doi.org/10.1093/oso/9780195309430.003.0023.

Full text
Abstract:
Antidepressant drug therapy is the cornerstone of treatment for major depression and is usually successful (Rosenbaum et al., 2005). Fifty percent of patients respond to the first antidepressant used, and 75% respond to one of the first three agents chosen if these agents represent different antidepressant classes. Insufficient dosage and duration of therapy are the most common causes of treatment failure. The required duration for a full therapeutic trial of any antidepressant is 6 to 8 weeks, but some patients require 10 to 12 weeks to achieve maximum benefit. Every patient being treated pharmacologically for depression should be educated about the course of recovery. Even if an antidepressant is ultimately successful, improvement in the first week or two may be minimal and involve primarily improved sleep or diminished anxiety. When more substantial improvements begin later, they may vary greatly on a day-to-day basis, and patients should be forewarned that the early course of recovery may be punctuated by unexpected brief dips in mood. Patients may also find that their energy, appetite, activity level, and social engagement improve before they notice a positive change in their moods. Thus, they look much improved to their friends and families before they feel better. Eventually, however, the full range of depressive symptoms resolves, and this improvement is sustained. During the course of antidepressant treatment, all patients must be asked about new or recurrent suicidal ideas, and their families should be told to report any evidence of self-harming actions or thoughts. Suicidal ideas, perhaps held in check by lack of energy to carry them out, may potentially develop into suicidal impulses or actions if a patient’s energy improves while severely depressed mood or hopelessness persist. Five classes of antidepressants will be described below: selective serotonin reuptake inhibitors (SSRIs), the serotonin norepinephrine reuptake inhibitor (SNRI) venlafaxine, the alpha2-adrenergic antagonist mirtazapine, the norepinephrinedopamine reuptake inhibitor (NDRI) bupropion, and tricyclic antidepressants (TCAs). There is little evidence that any individual antidepressant (or antidepressant class) is generally superior to another, so the sequence of drug selection is determined primarily by tolerability and safety considerations. The SSRIs are commonly used in the initial treatment of major depression.
APA, Harvard, Vancouver, ISO, and other styles
10

Huys, Quentin J. M. "A Valuation Framework for Emotions Applied to Depression and Recurrence." In Computational Psychiatry. The MIT Press, 2016. http://dx.doi.org/10.7551/mitpress/9780262035422.003.0015.

Full text
Abstract:
The burden of depression is substantially aggravated by relapses and recurrences, and these become more inevitable with every episode of depression. This chapter describes how computational psychiatry can provide a normative framework for emotions and an integrative approach to core cognitive components of depression and relapse. Central to this is the notion that emotions effectively imply a valuation; thus they are amenable to description and dissection by reinforcement-learning methods. It is argued that cognitive accounts of emotion can be viewed in terms of model-based valuation, and that automatic emotional responses relate to model-free valuation and the innate recruitment of fixed behavioral patterns. This model-based view captures phenomena such as helplessness, hopelessness, attributions, and stress sensitization. Considering it in more atomic algorithmic detail opens up the possibility of viewing rumination and emotion regulation in this same normative framework. The problem of treatment selection for relapse and recurrence prevention is outlined and suggestions made on how the computational framework of emotions might help improve this. The chapter closes with a brief overview of what we can hope to gain from computational psychiatry.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Recurrent brief depression"

1

ANGST, J., and B. HOCHSTRASSER. "RECURRENT BRIEF DEPRESSION." In IX World Congress of Psychiatry. WORLD SCIENTIFIC, 1994. http://dx.doi.org/10.1142/9789814440912_0061.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Recurrent brief depression' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography